PriceTargets.com logo

ESSA Pharma - EPIX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.50
  • Forecasted Upside: 205.56%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.40 As of 10/30/2024 03:53 PM ET
▼ -0.01 (-0.18%)

This chart shows the closing price for EPIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ESSA Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EPIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EPIX

Analyst Price Target is $16.50
▲ +205.56% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ESSA Pharma in the last 3 months. The average price target is $16.50, with a high forecast of $17.00 and a low forecast of $16.00. The average price target represents a 205.56% upside from the last price of $5.40.

This chart shows the closing price for EPIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in ESSA Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/16/2024OppenheimerReiterated RatingOutperform ➝ Outperform$17.00 ➝ $17.00
12/13/2023Jefferies Financial GroupBoost TargetBuy$15.00 ➝ $16.00
12/13/2023OppenheimerReiterated RatingOutperform ➝ Outperform$17.00
8/9/2023OppenheimerReiterated RatingOutperform ➝ Outperform$17.00
12/14/2022OppenheimerLower Target$23.00 ➝ $17.00
5/12/2022Piper SandlerLower Target$50.00 ➝ $20.00
8/16/2021OppenheimerLower TargetOutperform$36.00 ➝ $22.00
3/4/2021Piper SandlerInitiated CoverageOverweight$50.00
2/25/2021HC WainwrightLower TargetBuy$36.00 ➝ $32.00
2/12/2021Bloom BurtonReiterated RatingBuy
2/11/2021OppenheimerBoost TargetOutperform$20.00 ➝ $36.00
2/11/2021HC WainwrightBoost TargetBuy$17.00 ➝ $36.00
1/14/2021OppenheimerBoost TargetOutperform$9.00 ➝ $20.00
1/11/2021HC WainwrightBoost TargetBuy$10.00 ➝ $17.00
11/2/2020Jefferies Financial GroupInitiated CoverageBuy$17.00
8/10/2020OppenheimerReiterated RatingBuy$9.00
7/15/2020OppenheimerInitiated CoverageBuy$9.00
6/22/2020OppenheimerReiterated RatingBuy$8.00
5/24/2020Bloom BurtonReiterated RatingBuy$9.00
5/15/2020HC WainwrightReiterated RatingBuy
5/8/2020OppenheimerReiterated RatingBuy$8.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
ESSA Pharma logo
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $5.40
Low: $5.39
High: $5.57

50 Day Range

MA: $5.96
Low: $5.20
High: $7.10

52 Week Range

Now: $5.40
Low: $4.24
High: $11.67

Volume

6,131 shs

Average Volume

85,172 shs

Market Capitalization

$239.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of ESSA Pharma?

The following equities research analysts have issued reports on ESSA Pharma in the last year: Jefferies Financial Group Inc., and Oppenheimer Holdings Inc..
View the latest analyst ratings for EPIX.

What is the current price target for ESSA Pharma?

2 Wall Street analysts have set twelve-month price targets for ESSA Pharma in the last year. Their average twelve-month price target is $16.50, suggesting a possible upside of 205.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting EPIX will reach $17.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $16.00 for ESSA Pharma in the next year.
View the latest price targets for EPIX.

What is the current consensus analyst rating for ESSA Pharma?

ESSA Pharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EPIX will outperform the market and that investors should add to their positions of ESSA Pharma.
View the latest ratings for EPIX.

What other companies compete with ESSA Pharma?

Other companies that are similar to ESSA Pharma include Mesoblast, Arcutis Biotherapeutics, Applied Therapeutics, CARGO Therapeutics and Phibro Animal Health. Learn More about companies similar to ESSA Pharma.

How do I contact ESSA Pharma's investor relations team?

ESSA Pharma's physical mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company's listed phone number is 778-331-0962 and its investor relations email address is [email protected]. The official website for ESSA Pharma is www.essapharma.com. Learn More about contacing ESSA Pharma investor relations.